by NMS Group | Aug 1, 2025 | 2025, News
Nerviano, Italy – Shanghai, China 1 August 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced today the expansion of its presence in Asia with the establishment of Nerviano Medical...
by NMS Group | Jul 28, 2025 | 2025, News
NERVIANO, Italy, 24 July 2025 — Accelera, a global leader in preclinical in vivo toxicology and contract research services, today announced the appointment of Dr. Silvia Guionaud, PhD, DECVP, as Chief Executive Officer, effective immediately. Dr. Guionaud brings more...
by NMS Group | Jul 28, 2025 | 2025, News
NERVIANO, Italy, 28 July 2025 — BioNerviano (BioN), a company provides services to the community domiciled in Nerviano Bio-Park, today announced the appointment of Serena Alvino, MBA, CIPP/E, as Chief Executive Officer, effective immediately. Hugues Dolgos, Pharm.D.,...
by NMS Group | Jul 28, 2025 | 2025, News
NERVIANO, Italy, 28 July 2025 — NerPharMa (NPM), a renowned Contract Development and Manufacturing Organization (CDMO) specializing in oncology and in immunology, today announced the appointment of Serena Alvino, MBA, CIPP/E, as its new Chief Executive Officer,...
by NMS Group | Jul 23, 2025 | 2025, News
NERVIANO, Italy, 23 July 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced its strategic plan to focus its research and development resources to progress its three biological targets,...
by NMS Group | Jul 9, 2025 | 2025, News
Nerviano, Italy – 09 July 2025 – NMS Group S.p.A., the largest oncology-focused R&D organization in Italy, today announced the appointment of Mr. Victor Chu to its Board of Directors, effective immediately. Mr. Chu replaces Mr. Lincoln Pan, who has stepped...
Welcome and Check out our new motion picture!
Recent Comments